read more

first_img News | Brachytherapy Systems | August 14, 2019 Efficacy of Isoray’s Cesium Blu Showcased in Recent Studies August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medica read more Related Content News | Radiation Therapy | August 15, 2019 First Patient Enrolled in World’s Largest Brain Cancer Clinical Trial Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE Trial (Adaptive… read more March 14, 2012 – Mevion Medical Systems announced today it received CE mark certification for the Mevion S250 Proton Therapy System. This important commercial milestone indicates that Mevion has completed its development in compliance with the European Union’s Medical Device Directive. The CE Marking allows the MEVION S250 to be marketed, sold, and installed in the EuropeanUnion and in any country recognizing CE mark approval.Proton beam radiotherapy can accurately deliver targeted radiation doses with complete proton energy absorption at predictable tissue depth, thus allowing precise radiation delivery adjacent to critical structures and lower radiation doses to healthy structures. The availability of proton therapy has remained very limited however, due to the enormous cost, large footprint and technical complexity of traditional proton therapy systems.CE Marking of the MEVION S250 gives hospitals and cancer treatment centers throughout the European Union, and other regions where CE Marking is recognized, the ability to order, install, and treat patients with this revolutionary medical device. Powered by a TriNiobium CoreTM, the MEVION S250 significantly reduces the cost, size and complexity of proton therapy systems to levels similar to modern X-ray radiation therapy devices and brings accessibility, affordability and practicality to proton therapy.”We are very pleased to receive CE Marking certification for the MEVION S250, the final step to offer this first of its kind proton therapy system to healthcare providers and patients in the European Union,” said Joseph K. Jachinowski, CEO.In the United States, the MEVION S250 is pending USFDA 510(k) clearance.Mevion is concurrently installing three MEVION S250 Proton Therapy Systems in the United States. The first site at the Siteman Cancer Center in Barnes Jewish Hospital at St. Louis’ Washington University accepted delivery of its superconducting synchrocyclotron in October of 2011 and is now producing a powerful 250 MeV energy beam. The second and third installations at Robert Wood JohnsonUniversity Hospital in New Brunswick, NJ and Oklahoma University, OK are underway and scheduled to be completed later this year.American Shared Medical Services, a provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, owns about 1 percent of Mevion. AMS is developing proton therapy centers in Boston, Orlando, Fla. and Long Beach, Calif., which are expected to employ the MEVION S250 proton therapy device. The MEVION S250 is currently pending FDA 510(k) review.Mevion Medical Systems Inc. (formerly Still River Systems Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinical reality.Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.For more information: www.mevion.com FacebookTwitterLinkedInPrint分享 Feature | August 05, 2019 | Dave Fornell, Editor Most Popular Radiology and Radiotherapy Topics in July 2019 August 5, 2019 — Here is the list of the most popular content on the Imaging Technology New (ITN) magazine website fr read more Catalyst PT image courtesy of C-RAD News | Patient Positioning Radiation Therapy | August 07, 2019 Qfix kVue One Proton Couch Top Validated by Mevion Medical Systems Qfix and Mevion Medical Systems announced that a special version of the kVue One Proton couch top is now both validated… read more The top piece of content in July was a video interview explaining how Princess Margaret Cancer Center is using machine learning to create automated treatment plans. This was a hot topic at the American Association of Physicists in Medicine (AAPM) 2019 meeting in July.  Following radiation, the bone marrow shows nearly complete loss of blood cells in mice (left). Mice treated with the PTP-sigma inhibitor displayed rapid recovery of blood cells (purple, right). Credit: UCLA Broad Stem Cell Research Center/Nature Communications News | Radiation Therapy | August 16, 2019 Drug Accelerates Blood System’s Recovery After Radiation, Chemotherapy A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem… read more News | Proton Therapy | August 06, 2019 IBA Signs Contract to Install Proton Therapy Center in Kansas IBA (Ion Beam Applications S.A.) recently signed a contract and received the first payment for a Proteus One solution… read more The MD Anderson Proton Therapy Center expansion is expected to be completed in 2023. Rendering courtesy of Stantec. News | Radiation Therapy | August 02, 2019 Varian Showcases Cancer Care Systems and Software at AAPM 2019 Varian showcased systems and software from its cancer care portfolio, including the Identify Guidance System, at the… read more News | Proton Therapy | August 08, 2019 MD Anderson to Expand Proton Therapy Center The University of Texas MD Anderson Cancer Center unveiled plans to expand its Proton Therapy Center during a… read more News | Patient Positioning Radiation Therapy | August 15, 2019 Mevion and C-RAD Release Integration for Improved Proton Therapy Treatment Quality Mevion Medical Systems and C-RAD announced the integration between the C-RAD Catalyst PT and the Mevion S250i proton… read more News | March 16, 2012 Mevion Medical Receives CE Mark for its Proton Therapy System News | Radiation Oncology | July 31, 2019 Laura Dawson, M.D., FASTRO, Chosen as ASTRO President-elect The members of the American Society for Radiation Oncology (ASTRO) elected four new officers to ASTRO’s Board of… read morelast_img read more

Continue Reading